Back to List View Graph View

Lenvatinib

Lenvatinib is an orally administered multi-targeted tyrosine kinase inhibitor.

Where the papers sit

25 papers from the last 6 months study lenvatinib directly · updated from PubMed 16 Nov 2026

  • Immunotherapy in Kidney Cancer

    Pembrolizumab plus lenvatinib is being positioned as a first-line and later-line option for advanced renal cell carcinoma. Comparisons with nivolumab plus cabozantinib, cabozantinib alone, and belzutifan-based treatment focus on progression-free survival, safety, prognostic factors, and treatment value. Bayesian subgroup analyses and real-world data are refining which patients benefit most. Applications in head and neck and thyroid cancers broaden the strategy beyond renal cancer but remain less established.

    7 papers · 28%

  • Lenvatinib Resistance in Liver Cancer

    Resistance in hepatocellular carcinoma is being traced to interacting transcriptional, glycosylation, adhesion, and redox pathways. BBOX1-AS1 stabilizes MYC mRNA through IGF2BP1, while NDST2-driven EGFR N-glycosylation and RPRD1A–ITGA5–FAK signaling sustain resistance. HSPA6 stabilizes TXNRD1 and suppresses ferroptosis, whereas BAY-876 targets the GLUT1–SLC7A11–NADPH axis to restore sensitivity. Multi-omics subtyping and dose-intensity studies are moving the field toward molecularly guided treatment and resistance reversal.

    7 papers · 28%

  • Immunotherapy in Liver Cancer

    Immune checkpoint combinations are being tested to extend lenvatinib activity in unresectable hepatocellular carcinoma. Nivolumab or durvalumab–tremelimumab with lenvatinib and transarterial chemoembolisation are assessed by response and progression-free survival, including treatment sequencing around locoregional therapy. Real-world work keeps safety central, including immune toxicities such as myocarditis. The main open question is which timing and combination best converts angiogenic control into durable benefit.

    6 papers · 24%

  • Lenvatinib Combination Strategies

    Lenvatinib is being paired with immune activation, metabolic therapy, and engineered delivery systems to improve antitumor activity. Exosome vaccines with anti-PD-1, PD-L1 inhibition, and lenvatinib are tested alongside nanoparticles, hyaluronic acid–gelatin scaffolds, and cR10-modified liposomes. ADI-PEG 20 provides a separate combination approach in advanced hepatocellular carcinoma. Evidence remains mainly preclinical or case-based, leaving durability, tissue targeting, and clinical safety unresolved.

    5 papers · 20%

NEW DIRECTION

Lenvatinib is repurposed as an antigen-releasing component of a personalized cancer vaccine

The autochthonous hepatocellular carcinoma mouse study used lenvatinib not merely as an antiangiogenic or direct antitumor drug, but to release tumor neoantigens that could be captured through a dendritic-cell-derived exosome vaccine 42492521Jul. The resulting DEXPNX/lenvatinib treatment promoted dendritic-cell recruitment, antigen cross-presentation, de novo T-cell responses, and immunological memory, while addition of anti-PD-1 eradicated established tumors. This assigns lenvatinib a vaccine-enabling role—generating the antigenic material for individualized immune activation—that lies outside the treatment and resistance categories used by the other papers.

lenvatinib chemical structure

Papers

The 25 papers from the last 6 months that study lenvatinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Immunotherapy in Kidney Cancer (7)
  1. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European journal of cancer (Oxford, England : 1990) · 31 Aug 2026 PMID 42673705
  2. Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
  3. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet (London, England) · 12 Aug 2026 PMID 42586114
  4. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
  5. Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373289
  6. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. European journal of cancer (Oxford, England : 1990) · 4 Jun 2026 PMID 42241967
  7. Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034
Lenvatinib Resistance in Liver Cancer (7)
  1. BBOX1-AS1 mediates Lenvatinib resistance through IGF2BP1-dependent MYC mRNA stabilization. Biochemical and biophysical research communications · 18 Oct 2026 PMID 42892247
  2. BAY-876 restores lenvatinib sensitivity in resistant hepatocellular carcinoma cells by disrupting the GLUT1-SLC7A11-NADPH redox axis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 5 Oct 2026 PMID 42832095
  3. Early lenvatinib dose intensity is associated with survival in super-older adults (≥80 years) with hepatocellular carcinoma: a real-world comparison with atezolizumab-bevacizumab. European journal of gastroenterology & hepatology · 28 Aug 2026 PMID 42664455
  4. EGFR N-Glycosylation Catalyzed by NDST2 Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer research · 22 Jun 2026 PMID 42329862
  5. HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation-Mediated TXNRD1 Stabilization to Suppress Ferroptosis. Cancer research · 18 Jun 2026 PMID 42314062
  6. Comprehensive multi-omics analysis identifies cancer subtypes and prognostic signatures of hepatitis B virus-associated hepatocellular carcinoma. NPJ precision oncology · 4 Jun 2026 PMID 42243437
  7. RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis. Molecular biomedicine · 22 May 2026 PMID 42171939
Immunotherapy in Liver Cancer (6)
  1. Synchronizing immunity and angiogenesis in lung adenocarcinoma: bridging biological synergy and clinical translation. Cancer biology & therapy · 8 Sept 2026 PMID 42708433
  2. Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy. Liver international : official journal of the International Association for the Study of the Liver · 28 Aug 2026 PMID 42661423
  3. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. The Lancet. Oncology · 24 Aug 2026 PMID 42636832
  4. Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527085
  5. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
  6. Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284972
Lenvatinib Combination Strategies (5)
  1. Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice. Cell reports. Medicine · 23 Jul 2026 PMID 42492521
  2. The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379775
  3. Study on the inhibition of liver cancer progression by lenvatinib nanoparticles combined with hyaluronic acid/gelatin scaffold. Colloids and surfaces. B, Biointerfaces · 13 Jun 2026 PMID 42287829
  4. Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262196
  5. cR10-modified liposomes for efficient topical delivery of lenvatinib to the posterior segment: Enhanced suppression of choroidal neovascularization. International journal of pharmaceutics · 1 Jun 2026 PMID 42225176

By study type

Clinical trials (6)
  1. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European journal of cancer (Oxford, England : 1990) · 31 Aug 2026 PMID 42673705
  2. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. The Lancet. Oncology · 24 Aug 2026 PMID 42636832
  3. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet (London, England) · 12 Aug 2026 PMID 42586114
  4. Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373289
  5. Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284972
  6. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. European journal of cancer (Oxford, England : 1990) · 4 Jun 2026 PMID 42241967
Observational studies and case reports (6)
  1. Early lenvatinib dose intensity is associated with survival in super-older adults (≥80 years) with hepatocellular carcinoma: a real-world comparison with atezolizumab-bevacizumab. European journal of gastroenterology & hepatology · 28 Aug 2026 PMID 42664455
  2. Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy. Liver international : official journal of the International Association for the Study of the Liver · 28 Aug 2026 PMID 42661423
  3. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
  4. The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379775
  5. Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262196
  6. Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034
Human data, design not indexed (3)
  1. Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
  2. Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527085
  3. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
Preclinical: animal, cell and lab studies (9)
  1. BBOX1-AS1 mediates Lenvatinib resistance through IGF2BP1-dependent MYC mRNA stabilization. Biochemical and biophysical research communications · 18 Oct 2026 PMID 42892247
  2. BAY-876 restores lenvatinib sensitivity in resistant hepatocellular carcinoma cells by disrupting the GLUT1-SLC7A11-NADPH redox axis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 5 Oct 2026 PMID 42832095
  3. Synchronizing immunity and angiogenesis in lung adenocarcinoma: bridging biological synergy and clinical translation. Cancer biology & therapy · 8 Sept 2026 PMID 42708433
  4. Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice. Cell reports. Medicine · 23 Jul 2026 PMID 42492521
  5. EGFR N-Glycosylation Catalyzed by NDST2 Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer research · 22 Jun 2026 PMID 42329862
  6. HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation-Mediated TXNRD1 Stabilization to Suppress Ferroptosis. Cancer research · 18 Jun 2026 PMID 42314062
  7. Study on the inhibition of liver cancer progression by lenvatinib nanoparticles combined with hyaluronic acid/gelatin scaffold. Colloids and surfaces. B, Biointerfaces · 13 Jun 2026 PMID 42287829
  8. cR10-modified liposomes for efficient topical delivery of lenvatinib to the posterior segment: Enhanced suppression of choroidal neovascularization. International journal of pharmaceutics · 1 Jun 2026 PMID 42225176
  9. RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis. Molecular biomedicine · 22 May 2026 PMID 42171939
Unclassified: not yet indexed with MeSH (1)
  1. Comprehensive multi-omics analysis identifies cancer subtypes and prognostic signatures of hepatitis B virus-associated hepatocellular carcinoma. NPJ precision oncology · 4 Jun 2026 PMID 42243437